JF-NP-26 (Caged-Raseglurant) is a novel, inactive photocaged derivative of raseglurant / ADX-10059 (the mGlu5 receptor negative allosteric modulator (NAM)).
JF-NP-26 (Caged-Raseglurant) can be illuminated and uncaged by violet light (405 nM), to release raseglurant with spatial and temporal precision to allow local modulation of mGlu5 receptors. Unlike other caged compounds, JF-NP-26 can be uncaged by light within the visible spectrum which is particularly valuable for translation studies as opposed to UV light as visible spectrum light does not damage brain tissue.
JF-NP-26 (Caged-Raseglurant) is active in vivo, can be administered systemically and activated by LED-based illumination to induce JF-NP-26-mediated, light-dependent analgesia in both neuropathic and acute/tonic inflammatory pain models. No liver toxicity was observed in JF-NP-26 treatments used in tested pain models.
Recently shown (2022) that light-induced activation of JF-NP-26 in the ventrobasal thalamus causes rapid analgesia in a mouse model of breakthrough cancer pain (BTcP).
Solubility & Handling
Storage instructions
-20°C
Solubility overview
Soluble in DMSO (100mM)
Handling
This compound is light sensitive; exposure to light may affect compound performance. We therefore recommend storing the material in the dark and protecting from light.
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
Understanding purity and quality - a guide for life scientists
